The recall of blood pressure medications was prompted by the discovery that certain batches of potassium chloride extended-release capsules may not properly dissolve when ingested by patients. This could potentially lead to high potassium levels in the blood, or hyperkalemia, which can cause an irregular heartbeat and even cardiac arrest. The recall was initiated by Glenmark Pharmaceuticals and American Health Packaging as a precautionary measure.
The failed dissolution of the potassium chloride extended release capsules can cause high potassium levels in the blood, also known as hyperkalemia3. Hyperkalemia may lead to an irregular heartbeat, which can result in cardiac arrest2. Patients using the medication for high blood pressure management and prevention of heart or kidney failure are at risk.
Glenmark Pharmaceuticals voluntarily recalled 114 batches of Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K. The recall was due to failed dissolution, which could lead to hyperkalemia and potentially cause irregular heartbeat, cardiac arrest, and other adverse events5.